AEON Biopharma

Update in progress

AEON (NYSE American)

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing botulinum toxin products. Its lead product, ABP-450 (prabotulinumtoxinA) injection, has completed a Phase 2 study for cervical dystonia and is in a Phase 2 trial for chronic and episodic migraine, with additional research targeting gastroparesis and post-traumatic stress disorder. The company has license agreements with Daewoong Pharmaceutical Co., LTD., and Viatris Inc., and is based in Irvine, California.